Anmeldung erfolgt in Kürze...
Details werden geladen...
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval | The Manila Times
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration’s (FDA) accelerated approval of TZIELD® (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes.
Ähnliche Seiten
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum | The Manila Times
https://www.manilatimes.net/2026/05/28/tmt-newswire/globenewswire/scisparc-subsidiary-neurothera-labs-received-conditional-regulatory-approval-for-acquisition-of-cliniquantum/2353736MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval | The Manila Times
https://www.manilatimes.net/2026/05/30/tmt-newswire/globenewswire/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval/2354818Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/vera-therapeutics-announces-alignment-with-us-fda-on-earlier-origin-phase-3-analysis-to-support-potential-full-approval-for-atacicept-in-adults-with-iga-nephropathy/2356641Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market | The Manila Times
https://www.manilatimes.net/2026/06/04/tmt-newswire/pr-newswire/everest-medicines-enters-commercialization-license-agreement-with-mabworks-for-bejescin-in-the-asia-pacific-market/2358616Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development | The Manila Times
https://www.manilatimes.net/2026/06/04/tmt-newswire/globenewswire/ona-therapeutics-raises-866-million-series-b-to-advance-first-in-class-adcs-into-clinical-development/2358491